Pulmonary Arterial Hypertension Market By Product Type (Branded and Generics), By Route of Administration (Oral, Intravenous/ Subcutaneous, and Inhalational), By Drug Class (Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin and Prostacyclin Analogs, and PDE-5 Inhibitors), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
Report Overview The Pulmonary Arterial Hypertension Market Size is expected to be worth around US$ 13.6 billion by 2034 from US$ 8.1 billion in 2024, growing at a CAGR of 5.3% during...
